Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E40.58 EPS (ttm)1.82 Insider Own0.50% Shs Outstand1.54B Perf Week8.35%
Market Cap113.59B Forward P/E12.36 EPS next Y5.98 Insider Trans4.88% Shs Float1.53B Perf Month2.40%
Income3.07B PEG1.22 EPS next Q0.88 Inst Own94.00% Short Float6.00% Perf Quarter-10.12%
Sales11.20B P/S10.14 EPS this Y10.40% Inst Trans0.05% Short Ratio5.60 Perf Half Y10.26%
Book/sh7.41 P/B9.97 EPS next Y47.46% ROA13.70% Target Price97.67 Perf Year38.50%
Cash/sh1.39 P/C53.29 EPS next 5Y33.28% ROE28.30% 52W Range46.70 - 84.88 Perf YTD-1.65%
Dividend- P/FCF38.98 EPS past 5Y11.90% ROI18.70% 52W High-12.83% Beta0.66
Dividend %- Quick Ratio0.80 Sales past 5Y16.00% Gross Margin74.50% 52W Low58.44% ATR2.88
Employees6100 Current Ratio1.10 Sales Q/Q20.50% Oper. Margin40.40% RSI (14)53.61 Volatility2.62% 3.96%
OptionableYes Debt/Eq0.58 EPS Q/Q142.10% Profit Margin27.40% Rel Volume1.30 Prev Close73.86
ShortableYes LT Debt/Eq0.35 EarningsApr 22 AMC Payout0.00% Avg Volume16.38M Price73.99
Recom1.80 SMA204.63% SMA50-3.00% SMA2006.20% Volume20,443,492 Change0.18%
21-Feb-14Reiterated Barclays Overweight $90 → $95
10-Feb-14Reiterated Argus Buy $84 → $90
05-Feb-14Reiterated RBC Capital Mkts Outperform $90 → $96
05-Feb-14Reiterated Needham Buy $85 → $95
05-Feb-14Reiterated Maxim Group Buy $98 → $101
04-Feb-14Upgrade Robert W. Baird Neutral → Outperform $65 → $103
28-Jan-14Reiterated Deutsche Bank Buy $95 → $132
06-Jan-14Reiterated UBS Buy $80 → $102
02-Jan-14Reiterated Maxim Group Buy $89 → $98
20-Dec-13Reiterated RBC Capital Mkts Outperform $80 → $90
01-Nov-13Reiterated Argus Buy $70 → $84
30-Oct-13Reiterated RBC Capital Mkts Outperform $72 → $80
30-Oct-13Reiterated Barclays Overweight $68 → $74
26-Jul-13Reiterated Stifel Buy $65 → $75
26-Jul-13Reiterated RBC Capital Mkts Outperform $62 → $72
26-Jul-13Reiterated Barclays Overweight $65 → $68
26-Jul-13Downgrade Robert W. Baird Outperform → Neutral $55 → $65
13-Jun-13Upgrade Argus Hold → Buy
17-May-13Reiterated UBS Buy $63 → $67
03-May-13Reiterated Oppenheimer Outperform $59 → $61
24-Apr-14 02:32PM  Celgene Beats on First-Quarter Earnings: What's Next? at Motley Fool
10:29AM  Biotech Falls Again as Celgene Suffers at Barrons.com
07:06AM  Ambit Biosciences Slumps: AMBI Falls 7.1% in Session Zacks
06:00AM  Strategists Dismiss Nasdaq, Nikkei Wobbles at TheStreet
23-Apr-14 11:44PM  Here's why the biotech bounce may be short lived Talking Numbers
06:32PM  Should You Invest in Gilead Sciences, Inc. Today? at Motley Fool
06:30PM  [video] Gilead's Earnings: Diving Deeper Into The Numbers With $84,000 Sovaldi Drug at TheStreet
04:52PM  This company just had the best new drug launch of all-time Talking Numbers
04:23PM  AbbVie Files for HCV Combination Therapy in U.S. Zacks
04:05PM  Stocks ended the day down after mixed earnings and housing market news Hot Stock Minute
04:04PM  Earnings Roundup: What You Need to Know About Gilead's Blockbuster Quarter at Motley Fool
03:38PM  Biogen raises outlook as new MS drug again tops forecasts Reuters
03:35PM  Why Investors Are Not Chasing Gilead Endlessly Higher at 24/7 Wall St.
03:35PM  Why Investors Are Not Chasing Gilead Endlessly Higher 24/7 Wall St.
03:10PM  Earnings from Gilead and Amgen Put These ETFs in Focus Zacks
01:40PM  Stocks Trading Lower In Afternoon Action at Investor's Business Daily
12:21PM  Gilead Sciences: "Officially a Value Stock" at Barrons.com
12:20PM  Midday movers: Facebook, Gilead Sciences & More at CNBC
11:46AM  What We Learned from Gilead Sciences' First Quarter Earnings at Motley Fool
11:39AM  Gilead, Illumina Q1 Earnings Win Wall Street's Love at Investor's Business Daily
11:37AM  Biotech ETF Loses Ground as Earnings Disappoint at Barrons.com
11:34AM  Gilead climbs after hep C drug sales top $2B in Q1 at theflyonthewall.com
11:20AM  'Croci' pushes the limits of value investing at Financial Times
11:14AM  [$$] Gilead Sciences' Earnings Triple on New Hepatitis Drug at The Wall Street Journal
11:00AM  Strong Q1 Earnings at Gilead on Stellar Sovaldi Sales Zacks
10:43AM  [$$] Gilead Sciences' Earnings Triple on New Hepatitis Drug at The Wall Street Journal
10:18AM  [video] Gilead's Hepatitis C Drug Solvaldi Delivers Healthy Earnings at TheStreet
10:04AM  Say Hello to the New Fastest Growing Drug in History! at Motley Fool
10:04AM  [video] Tech & biotech plays for your portfolio at CNBC
09:49AM  [$$] Gilead Sciences' Earnings Triple on New Hepatitis Drug at The Wall Street Journal
09:49AM  Gilead (GILD) On Momo Momentum Watch Today at TheStreet
09:43AM  Is there anything wrong with an $84,000 prescription drug? The Daily Ticker
09:24AM  Biogen raises outlook as new MS drug again tops forecasts Reuters
09:05AM  Gilead: X-Marks The Spot For Sovaldi Sales at Seeking Alpha
09:04AM  Delta, Boeing shares take off; Plug Power drops at MarketWatch
09:04AM  Today's Health Care Stocks to Watch: Illumina Inc., Intuitive Surgical Inc. and Gilead Sciences at Motley Fool
09:01AM  Why Gilead Sciences (GILD) Stock Is Higher This Morning at TheStreet
08:52AM  Sovaldi's Q1 Is A Home Run With Men On Base; Why Gilead May Triple From Here at Seeking Alpha
08:40AM  Gilead's Sovaldi durability questions remain but upside justified, says Baird theflyonthewall.com
08:40AM  Amgen's Q1 Earnings Decline Y/Y Zacks
07:57AM  [video] Morning Movers: Gilead Sciences Revenue Soars at Bloomberg
07:31AM  Alliance Fiber Optic, Talisman Energy, Gilead Sciences, Biogen Idec and Alexion Pharmaceuticals highlighted as Zacks Bull and Bear of the Day Zacks
05:34AM  Gilead 'officially a value stock' after Q1 results, says Piper Jaffray theflyonthewall.com
01:30AM  [$$] Gilead Sciences' Earnings Triple on New Hepatitis Drug at The Wall Street Journal
12:18AM  [$$] Gilead Sciences' Earnings Triple on New Hepatitis Drug at The Wall Street Journal
22-Apr-14 11:55PM  [$$] Gilead Sciences' Earnings Triple on New Hepatitis Drug at The Wall Street Journal
11:10PM  Gilead Sciences' CEO Discusses Q1 2014 Results - Earnings Call Transcript Seeking Alpha
10:14PM  Asia shares mixed after HSBC China flash PMI; Japan's Seibu rallies at CNBC
09:58PM  Gilead jumps as sales of hepatitis C drug soars at USA TODAY
09:00PM  Asia shares gain ahead of HSBC China flash PMI at CNBC
08:53PM  [$$] Gilead Sciences' Earnings Triple on New Hepatitis Drug at The Wall Street Journal
07:09PM  On The Fly: After Hours Movers at theflyonthewall.com
06:43PM  Gilead Soars As Hep C Drug Shatters Views; Amgen Misses at Investor's Business Daily
06:43PM  Gilead Earnings Surge As Hep C Drug Shatters Views at Investor's Business Daily
06:43PM  Gilead Blows Out First Quarter at Investor's Business Daily
06:39PM  Gilead profit triples, hepatitis C drug sales beat by $1 bln Reuters
06:37PM  Biz Break: Gilead's new hepatitis C drug produces huge sales in debut quarter at San Jose Mercury News
06:17PM  Gilead Revenue Soars on Hepatitis C Drug at New York Times
06:17PM  Gilead Revenue Soars on Hepatitis C Drug at New York Times
06:17PM  Gilead says 1Q sales of Sovaldi totaled $2.27B AP
06:13PM  [$$] Gilead's Results Boosted by Hepatitis Drug at The Wall Street Journal
06:10PM  Gilead's Strong Quarter May Stem Stock Slide at The Wall Street Journal
05:55PM  Gilead shares climb; AT&T, Amgen shares fall at MarketWatch
05:50PM  Gilead Sales Double on $1,000 Hepatitis C Pills at BusinessWeek
05:46PM  Gilead scores big on earnings with new drug, but investors getting wary at MarketWatch
05:41PM  Gilead says 1Q sales of Sovaldi totaled $2.27B AP
05:32PM  [$$] Gilead's Results Boosted by Hepatitis Drug at The Wall Street Journal
05:12PM  Biotech Company Gilead Just Destroyed All Expectations For Sales Of Its New Hepatitis C Drug Business Insider
05:12PM  Biotech Company Gilead Just Destroyed All Expectations For Sales Of Its New Hepatitis C Drug Business Insider
05:11PM  Gilead Sciences Drops Jaws With a 209% Increase in Q1 Net Income at Motley Fool
05:11PM  Gilead profit triples, hepatitis C drug sales total $2.3 bln Reuters
05:05PM  Gilead shares climb; AT&T, Amgen shares fall at MarketWatch
05:04PM  [$$] Gilead's Results Boosted by Hepatitis Drug at The Wall Street Journal
05:04PM  Gilead earnings buoyed by Hepatitis-C drug at MarketWatch
05:00PM  Gilead Sciences: Fantastic Earnings, "Remarkable" Sovaldi Sales at Barrons.com
04:48PM  An Earnings Tale of Two Biotechs Gilead vs. Amgen 24/7 Wall St.
04:33PM  [$$] Gilead's Results Boosted by Hepatitis Drug at The Wall Street Journal
04:28PM  Will Gilead Sciences (GILD) Earnings Boost The Stock In After-Market Trading? at TheStreet
04:23PM  Gilead profit triples, hepatitis C drug revenue reaches $2.3 bln Reuters
04:22PM  Gilead beats expectations; Sovaldi sales hit $2.3 bln at MarketWatch
04:15PM  Gilead Sciences Earnings Call scheduled for 4:15 pm ET today CCBN
04:14PM  Gilead Sciences: Fantastic Earnings, "Remarkable" Sovaldi Sales at Barrons.com
04:09PM  [video] Gilead earnings blowout: Pro at CNBC
04:08PM  GILEAD SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib EDGAR Online
04:07PM  [video] Big Q1 for Gilead at CNBC
04:02PM  Gilead Sciences Announces First Quarter 2014 Financial Results Business Wire
02:06PM  Gilead Sciences: Can Earnings Cure What Ails It? at Barrons.com
01:07PM  [video] Biggest biotech players at CNBC
10:46AM  Stocks to watch: MCD, GILD, CMCSA, NFLX Hot Stock Minute
10:00AM  Synageva Heading For Big Disappointment at Seeking Alpha
09:32AM  Why Johnson & Johnson Is Outperforming the Dow at Motley Fool
09:02AM  Today's Health Care Stocks to Watch: Eli Lilly and Co, GlaxoSmithKline plc, Novartis AG, and Gilead Sciences, Inc. at Motley Fool
07:37AM  Big moves in Pharma; McDonald's earnings; Gas prices on the rise Hot Stock Minute
07:34AM  Gilead Sciences Earnings Call scheduled for 4:15 pm ET today CCBN
07:24AM  Drugmaker Gilead's earnings could move markets at USA TODAY
07:11AM  Why Earnings Season Could Be Great for Gilead Sciences (GILD) Zacks
07:07AM  Q1 2014 Gilead Sciences Earnings Release - 4:05 pm ET CCBN
21-Apr-14 10:22PM  The closest thing to a sure thing for your money at MarketWatch
06:34PM  What to Watch for in Biotech Earnings This Week at Motley Fool
06:34PM  Gilead Sovaldi Drug Sales Key In Q1 Earnings Report at Investor's Business Daily
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. The company's products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in adult patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages for the treatment of HIV, liver, oncology/inflammation, cardiovascular, and respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 14Option Exercise16.4090,0001,475,550209,302Apr 16 12:34 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 14Sale67.0390,0006,032,482119,302Apr 16 12:34 PM
Cogan John FrancisDirectorApr 08Option Exercise14.345,00071,68844,542Apr 10 02:52 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Option Exercise24.4316,728408,68945,290Apr 10 03:52 PM
Cogan John FrancisDirectorApr 08Sale70.555,000352,75539,542Apr 10 02:52 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Sale70.5316,7281,179,78228,562Apr 10 03:52 PM
MARTIN JOHN CChairman and CEOApr 01Option Exercise8.01140,6251,125,7034,570,012Apr 03 03:20 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Option Exercise21.5811,000237,325145,694Apr 03 03:20 PM
Whitley Richard JamesDirectorApr 01Option Exercise26.995,000134,95018,116Apr 03 04:00 PM
MARTIN JOHN CChairman and CEOApr 01Sale73.26140,62510,302,0284,429,387Apr 03 03:20 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale73.2013,000951,640132,694Apr 03 03:20 PM
Whitley Richard JamesDirectorApr 01Sale73.095,000365,45013,116Apr 03 04:00 PM
Cogan John FrancisDirectorMar 14Option Exercise14.3414,000200,72553,542Mar 18 12:56 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMar 14Option Exercise16.4090,0001,475,550209,302Mar 18 01:36 PM
Cogan John FrancisDirectorMar 14Sale76.4414,0001,070,10139,542Mar 18 12:56 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMar 14Sale75.8990,0006,829,705119,302Mar 18 01:36 PM
Carter Paul RutherfordEVP Commercial OpsMar 10Option Exercise21.5816,728360,90745,290Mar 12 01:39 PM
Carter Paul RutherfordEVP Commercial OpsMar 10Sale79.3216,7281,326,83328,562Mar 12 01:39 PM
Alton Gregg HEVP, Corp & Med AffairsMar 03Option Exercise21.5831,000668,825117,484Mar 05 02:50 PM
MARTIN JOHN CChairman and CEOMar 03Option Exercise8.01140,6251,125,7034,397,860Mar 05 02:51 PM
Alton Gregg HEVP, Corp & Med AffairsMar 03Sale81.8433,0002,700,68784,484Mar 05 02:50 PM
MARTIN JOHN CChairman and CEOMar 03Sale81.74140,62511,495,3264,257,235Mar 05 02:51 PM
Washington Robin LEVP, CFOFeb 28Option Exercise22.3030,600682,49080,432Mar 04 09:09 PM
Carter Paul RutherfordEVP Commercial OpsFeb 28Option Exercise24.0099,0002,375,550114,842Mar 04 02:56 PM
Washington Robin LEVP, CFOFeb 28Sale83.6530,6002,559,63549,832Mar 04 09:09 PM
Carter Paul RutherfordEVP Commercial OpsFeb 28Sale83.5599,0008,271,93515,842Mar 04 02:56 PM
MOORE NICHOLAS GDirectorFeb 26Option Exercise26.6220,000532,30020,000Feb 28 12:50 PM
MOORE NICHOLAS GDirectorFeb 26Sale84.0520,0001,681,0700Feb 28 12:50 PM
Washington Robin LEVP, CFOFeb 21Option Exercise23.605,000118,00054,832Feb 25 03:41 PM
Washington Robin LEVP, CFOFeb 21Sale83.245,000416,21849,832Feb 25 03:41 PM
MOORE NICHOLAS GDirectorFeb 19Option Exercise22.0219,068419,78219,068Feb 21 02:32 PM
Washington Robin LEVP, CFOFeb 19Sale83.3696880,69249,832Feb 21 03:41 PM
MOORE NICHOLAS GDirectorFeb 19Sale83.1219,0681,584,9900Feb 21 02:32 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 14Option Exercise14.5090,0001,305,225158,124Feb 19 02:09 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 14Sale81.3690,0007,322,22268,124Feb 19 02:09 PM
Carter Paul RutherfordEVP Commercial OpsFeb 10Option Exercise21.5816,728360,90731,861Feb 12 04:44 PM
Carter Paul RutherfordEVP Commercial OpsFeb 10Sale79.1016,7281,323,19815,133Feb 12 04:44 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 03Option Exercise21.5831,000668,825118,516Feb 05 06:34 PM
MARTIN JOHN CChairman and CEOFeb 03Option Exercise8.01140,6251,125,7034,396,892Feb 05 06:53 PM
MARTIN JOHN CChairman and CEOFeb 03Sale79.96140,62511,244,0894,256,267Feb 05 06:53 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 03Sale80.7833,0002,665,59385,516Feb 05 06:34 PM
YOUNG KEVINEVP, Commercial OperationsJan 23Option Exercise16.40100,0001,639,500316,418Jan 27 08:07 PM
YOUNG KEVINEVP, Commercial OperationsJan 23Sale81.44100,0008,144,150216,418Jan 27 08:07 PM
Alton Gregg HEVP, Corp & Med AffairsJan 21Option Exercise19.94120,0002,392,393152,938Jan 22 07:15 PM
Alton Gregg HEVP, Corp & Med AffairsJan 21Sale80.00120,0009,600,00032,938Jan 22 07:15 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 14Option Exercise14.5090,0001,305,22590,000Jan 16 02:15 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 14Sale74.2390,0006,681,1470Jan 16 02:15 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Option Exercise19.11111,0002,121,519145,938Jan 06 05:39 PM
MARTIN JOHN CChairman and CEOJan 02Option Exercise8.01140,6251,125,7034,197,746Jan 06 05:38 PM
Washington Robin LSVP, CFOJan 02Option Exercise22.4935,600800,49035,600Jan 06 05:39 PM
Washington Robin LSVP, CFOJan 02Sale75.0335,6002,671,2140Jan 06 05:39 PM
MARTIN JOHN CChairman and CEOJan 02Sale75.02140,62510,550,1804,057,121Jan 06 05:38 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Sale75.01113,0008,476,56432,938Jan 06 05:39 PM
YOUNG KEVINEVP, Commercial OperationsDec 20Option Exercise16.4075,0001,229,625236,840Dec 24 01:41 PM
YOUNG KEVINEVP, Commercial OperationsDec 20Sale74.1975,0005,564,453161,840Dec 24 01:41 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSODec 16Option Exercise14.5090,0001,305,22590,000Dec 18 02:16 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSODec 16Sale71.7590,0006,457,9410Dec 18 02:16 PM
MARTIN JOHN CChairman and CEODec 02Option Exercise7.63282,2422,154,2124,339,363Dec 04 03:55 PM
MARTIN JOHN CChairman and CEODec 02Sale74.26282,24220,960,6974,057,121Dec 04 03:55 PM
MILLIGAN JOHN FPresident and COONov 25Option Exercise7.8125,588199,954590,362Nov 26 06:20 PM
YOUNG KEVINEVP, Commercial OperationsNov 22Option Exercise16.4075,0001,229,625236,840Nov 25 03:25 PM
YOUNG KEVINEVP, Commercial OperationsNov 22Sale74.3475,0005,575,549161,840Nov 25 03:25 PM
MILLIGAN JOHN FPresident and COONov 21Option Exercise7.63395,6343,019,677960,408Nov 25 01:16 PM
MILLIGAN JOHN FPresident and COONov 21Sale71.57395,63428,316,396564,774Nov 25 01:16 PM
DAVIGNON ETIENNEDirectorNov 21Sale71.579,778699,7931,160,186Nov 25 03:13 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSONov 14Option Exercise14.5090,0001,305,22590,000Nov 18 03:12 PM
MILLIGAN JOHN FPresident and COONov 14Option Exercise7.63395,6353,019,684960,409Nov 18 03:22 PM
MILLIGAN JOHN FPresident and COONov 14Sale68.86395,63527,242,833564,774Nov 18 03:22 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSONov 14Sale68.8690,0006,197,2920Nov 18 03:12 PM
MILLIGAN JOHN FPresident and COONov 07Option Exercise7.63395,6353,019,684960,409Nov 12 12:44 PM
MILLIGAN JOHN FPresident and COONov 07Sale67.51395,63526,710,875564,774Nov 12 12:44 PM
Washington Robin LSVP, CFONov 06Sale68.632,869196,91022,826Nov 08 05:28 PM
Washington Robin LSVP, CFONov 05Option Exercise0.006,000028,826Nov 07 07:14 PM
Alton Gregg HEVP, Corp & Med AffairsNov 01Option Exercise19.0926,000496,21068,938Nov 05 07:58 PM
MARTIN JOHN CChairman and CEONov 01Option Exercise7.63282,2422,154,2124,339,363Nov 05 08:14 PM
MARTIN JOHN CChairman and CEONov 01Sale70.83282,24219,990,2134,057,121Nov 05 08:14 PM
Alton Gregg HEVP, Corp & Med AffairsNov 01Sale70.7930,0002,123,70838,938Nov 05 07:58 PM
YOUNG KEVINEVP, Commercial OperationsOct 23Option Exercise16.4075,0001,229,625236,840Oct 25 05:09 PM
YOUNG KEVINEVP, Commercial OperationsOct 23Sale68.5675,0005,142,000161,840Oct 25 05:09 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOOct 14Option Exercise14.5090,0001,305,2252,249,643Oct 16 06:05 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOOct 14Sale62.5490,0005,628,1872,159,643Oct 16 06:05 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Option Exercise17.5626,000456,55472,938Oct 03 04:11 PM
MARTIN JOHN CChairman and CEOOct 01Option Exercise7.63282,2422,154,2124,339,363Oct 03 04:10 PM
MARTIN JOHN CChairman and CEOOct 01Sale62.70282,24217,696,5454,057,121Oct 03 04:10 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Sale62.7530,0001,882,54942,938Oct 03 04:11 PM
Washington Robin LSVP, CFOSep 30Option Exercise22.4935,600800,49062,730Oct 02 05:58 PM
Washington Robin LSVP, CFOSep 30Sale63.2835,6002,252,91627,130Oct 02 05:58 PM
YOUNG KEVINEVP, Commercial OperationsSep 23Option Exercise15.35100,0001,534,558261,840Sep 25 06:21 PM
YOUNG KEVINEVP, Commercial OperationsSep 23Sale62.88100,0006,288,189161,840Sep 25 06:21 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOSep 16Option Exercise14.5090,0001,305,2252,249,643Sep 18 04:38 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOSep 16Sale63.1190,0005,679,9622,159,643Sep 18 04:38 PM
Alton Gregg HEVP, Corp & Med AffairsSep 03Option Exercise16.4026,000426,27076,938Sep 05 07:43 PM
MARTIN JOHN CChairman and CEOSep 03Option Exercise7.63282,2422,154,2124,339,363Sep 05 07:44 PM
MARTIN JOHN CChairman and CEOSep 03Sale60.97282,24217,209,4904,057,121Sep 05 07:44 PM
Alton Gregg HEVP, Corp & Med AffairsSep 03Sale60.9930,0001,829,66746,938Sep 05 07:43 PM
MOORE NICHOLAS GDirectorAug 30Option Exercise20.55151,7203,118,014151,720Sep 04 07:09 PM
MOORE NICHOLAS GDirectorAug 30Sale60.42151,7209,166,5830Sep 04 07:09 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOAug 14Option Exercise14.5090,0001,305,2252,249,643Aug 16 12:22 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOAug 14Sale58.7790,0005,288,8812,159,643Aug 16 12:22 PM
Cogan John FrancisDirectorAug 02Option Exercise10.9917,000186,87356,542Aug 05 04:12 PM